Reversal of boswellic acid analog BA145 induced caspase dependent apoptosis by PI3K inhibitor LY294002 and MEK inhibitor PD98059

Apoptosis

Volumn 18, Issue 12, 2013, Pages 1561-1573

  Pathania, Anup S ^a,b   Joshi, Amit ^c   Kumar, Suresh ^b   Guru, Santosh K ^b   Bhushan, Shashi ^b   Sharma, Parduman R ^b   Bhat, Wajid W ^b   Saxena, Ajit K ^b   Singh, Jaswant ^b   Shah, Bhahwal A ^b   Andotra, Samar S ^b   Taneja, Subhash C ^b   Malik, Fayaz A ^a,b   Kumar, Ajay ^b  

^a NATIONAL CHEMICAL LABORATORY   (India)

^b CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

^c SGGS College Sector 26   (India)

Author keywords

Apoptosis; Boswellic acids; Caspases; LY294002; PD98059

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; ANTINEOPLASTIC AGENT; BA 145; BOSWELLIC ACID; CASPASE; CASPASE 8; CASPASE 9; CYCLIN D1; CYCLIN E; CYTOCHROME C; PROTEIN P21; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL STRAIN HL 60; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; MITOCHONDRIAL MEMBRANE POTENTIAL; MUTATIONAL ANALYSIS; MYELOID LEUKEMIA; OXIDATIVE STRESS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRUCTURE ACTIVITY RELATION; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; CHROMONES; FLAVONOIDS; HL-60 CELLS; HUMANS; LEUKEMIA; MAP KINASE SIGNALING SYSTEM; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RETINOBLASTOMA PROTEIN; TRITERPENES;

EID: 84889091800     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-013-0889-4     Document Type: Article

References (33)

1. Dhillon AS, Hagan S, Rath O, Kolch W (2007) MAP kinase signalling pathways in cancer. Oncogene 26:3279-3290
2. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773:1263-1284
3. Bos JL (1989) Ras oncogenes in human cancer: a review. Cancer Res 49:4682-4689
4. Gorman DMO, McKenna SL, McMahon AJ, Knox KA, Cotte TG (2000) Sensitisation of HL-60 human leukemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3kinase survival signals. Leukemia 14:602-611
5. Cagnol S, Chambard JC (2010) ERK and cell death: mechanisms of ERK-induced cell death - apoptosis, autophagy and senescence. FEBS J 277:2-21
6. Wang X, Martindale JL, Holbrook NJ (2000) Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem 275:39435-39443
7. Campbell PM, Groehler AL, Lee KM, Ouellette MM, Khazak V, Der CJ (2007) K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signalling. Cancer Res 67:2098-2106
8. Vivanco I, Sawyers CL (2002) The Phosphoinositol 3-kinase-Akt pathway in human cancer. Nat Rev Cancer 2:489-501
9. Wullschleger S, Loewith R, Hall MN (2006) TOR signalling in growth and metabolism. Cell 124:471-484
10. Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide3 kinase pathway in cancer. Nat Rev Drug Discov 8:627-644
11. Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9:550-562
12. Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LS, Gunn S, Smetzer L, Mays TA, Kaiser B, Wick MJ, Alvarez C, Cavazos A, Mangold GL, Patnaik A (2012) The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 18:2316-2325
13. Courtney KD, Corcoran RB, Engelmann JA (2010) The PI3K pathway as drug target in human cancer. J Clin Oncol 28:1075-1083
14. Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Bäsecke J, Stivala F, Donia M, Fagone P, Malaponte G, Mazzarino MC, Nicoletti F, Libra M, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, Milella M, Tafuri A, Bonati A, Evangelisti C, Cocco L, Martelli AM, McCubrey JA (2011) Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2:135-164
15. Xia L, Chen D, Han R, Fang Q, Waxman S, Jing Y (2005) Boswellic acid acetate induces apoptosis through caspase-mediated pathways in myeloid leukemia cells. Mol Cancer Ther 4:381-388
16. Lu M, Xia L, Hua H, Jing Y (2008) Acetyl-keto-b-boswellic acid induces apoptosis through a death receptor 5 mediated pathway in prostate cancer cells. Cancer Res 68:1180-1186
17. Shah BA, Qazi GN, Taneja SC (2009) Boswellic acids: a group of medicinally important compounds. Nat Prod Rep 26:72-89
18. Kumar A, Shah BA, Singh S, Hamid A, Singh SK, Sethi VK, Saxena AK, Singh J, Taneja SC (2012) Acyl derivatives of boswellic acids as inhibitors of NF-κB and STATs. Bioorg Med Chem Lett 22:431-435
19. Hall A, Marshall CJ, Spurr NK, Weiss RA (1983) Identification of transforming gene in two human sarcoma cell lines as a new member of the ras gene family located on chromosome 1. Nature 303:396-400
20. Collard JG, Van Beek WP, Janssen JW, Schijven JF (1985) Transfection by human oncogenes: concomitant induction of tumorigenicity and tumor associated membrane alterations. Int J Cancer 35:207-213
21. Mohr S, Mccormick TS, Lapetina EG (1998) Macrophages resistant to endogenously generated nitric oxide-mediated apoptosis are hypersensitive to exogenously added nitric oxide donors: dichotomous apoptotic response independent of caspase 3 and reversal by the mitogen-activated protein kinase kinase (MEK) inhibitor PD98059. Proc Natl Acad Sci USA 95:5045-5050
22. Tang D, Wu D, Hirao A, Lahti JM, Liu L, Mazza B, Kidd VJ, Mak TW, Ingram AJ (2002) ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J Biol Chem 277:12710-12717
23. Dhanalakshmi S, Agarwal C, Singh RP, Agarwal R (2005) Silibinin up-regulates DNA-protein kinase-dependent p53 activation to enhance UVB-induced apoptosis in mouse epithelial JB6 Cells. J Biol Chem 280:20375-20383
24. Bar J, Lukaschuk N, Zalcenstein A, Wilder S, Seger R, Oren M (2005) The PI3K inhibitor LY294002 prevents p53 induction by DNA damage and attenuates chemotherapy-induced apoptosis. Cell Death Differ 12:1578-1587
25. Carbott DE, Duan L, Davis MA (2002) Phosphoinositol 3 kinase inhibitor, LY294002 increases bcl-2 protein and inhibits okadaic acid-induced apoptosis in Bcl-2 expressing renal epithelial cells. Apoptosis 7:69-76
26. Ferri KF, Kroemer G (2001) Organelle-specific initiation of cell death pathways. Nat Cell Biol 3:E255-E263
27. Roos WP, Kaina B (2006) DNA damage-induced cell death by apoptosis. Trends Mol Med 12:440-450
28. Liu JJ, Duan RD (2009) LY294002 enhances boswellic acid induced apoptosis in colon cancer cells. Anticancer Res 29:2987-2991
29. Castellano E, Downwar J (2011) RAS Interaction with PI3K: more than Just another effector pathway. Genes Cancer 2:261-274
30. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD, Downward J (1994) Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370:527-532
31. Zelivianski S, Spellman M, Kellerman M, Kakitelashvilli V, Zhou XW, Lugo E, Lee MS, Taylor R, Davis TL, Hauke R, Lin MF (2003) Erk inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. Int J Cancer 107:478-485
32. Opel D, Westhoff MA, Bender A, Braun V, Debatin KM, Fulda S (2008) Phosphatidylinositol 3-Kinase inhibition broadly sensitizes glioblastoma cells to death receptor and drug-induced apoptosis. Cancer Res 68:6271-6280
33. Mazumder S, Gong B, Almasan A (2000) Cyclin E induction by genotoxic stress leads to apoptosis of hematopoietic cells. Oncogene 19:2828-2835